Luminent 's website can be found at http://www.com."
HER-2/neu protein analysis aids in the management of breast cancer
patients and is used by physicians to aid in prognosis and prediction of
therapy outcomes for breast cancer.

ri talvard

Luminent Mortgage Capital Inc. Announces Gail P. Seneca to Focus Exclusively on Luminent

Because of those
risks, Luminent's actual results, performance or achievements may differ
materially in adverse ways from the results, performance or achievements
contemplated by its forward-looking statements.

CONTACT: Christopher J.

royskt umbo

talvard studenta

Seneca, its Chairman and Chief Executive Officer,
will focus her time and energy exclusively on Luminent after her departure
from Seneca Capital Management. Ms.
"Any financial company would be proud to claim Gail Seneca as its Chief
Executive Officer," said Bruce Miller, the lead independent director. The matters described in these
forward-looking statements are subject to known and unknown risks,
uncertainties and other unpredictable factors, many of which are beyond
Luminent's control. These forward-looking
statements are subject to numerous risks and uncertainties, and actual results
may vary materially.

tar ri

This news release contains forward-looking statements that predict or
describe future events or trends.sec. Hall Christopher Gleeson
Chief Financial Officer President and CEO
(336) 290 -8721 (520) 229-3787

Nick Malden
Chief Financial Officer
(520) 229-3857

endam kfum

Important factors that may affect such forward-looking statements
include, without limitation: TriPath Oncology may be unable to successfully
develop and commercialize products and services when anticipated, if at all;
TriPath Imaging's products may not achieve or maintain market acceptance to
the degree anticipated; TriPath Imaging and TriPath Oncology's products may
not receive FDA or other required regulatory approval when expected, if at
all; and other risks detailed in TriPath Imaging's filings with the Securities
and Exchange Commission, including those described in TriPath Imaging's Annual
Report on Form 10-K for the year ended December 31, 2004. We undertake no
obligation following the date of this release to update or revise our forward-
looking statements or to update the reasons actual results could differ
materially from those anticipated in forward-looking statements . We caution
you not to place undue reliance upon any such forward-looking statements,
which speak only as of the date such statements are made.

um fer

"The
board of Luminent is delighted that Gail will focus her energies exclusively
at Luminent for the benefit of its shareholders.gov.

talvard um

Food and Drug Administration for the Ventana Image
Analysis System (VIAS(TM)) when used with tissues stained for HER-2/neu.
Sohmer, M.
Ventana's drug discovery systems are used to accelerate the discovery of new
drug targets and evaluate the safety of new drug compounds. We cannot guarantee any future operating
results, activity, performance, or achievement.

barna lundar

"
Luminent was formed in April 2003, completed its initial public offering
in December 2003 and trades on the New York Stock Exchange under the ticker
"LUM.com.C., and TUCSON, Ariz.,
TriPath Imaging Inc.
TriPath Imaging, Inc. TriPath Oncology, a wholly owned subsidiary of TriPath Imaging,
develops molecular diagnostic products for malignant melanoma and cancers of
the cervix, breast, ovary and prostate.

TriPath Imaging Safe Harbor Statement
Investors are cautioned that statements in this press release that are not
strictly historical statements constitute forward-looking statements which
involve risks and uncertainties that could cause actual results and outcomes
to differ materially from what is expressed in those forward-looking
statements.

barna er

BURLINGTON, N. (Nasdaq: TPTH) and Ventana Medical Systems , Inc.
(Nasdaq: VMSI), announced today that TriPath Imaging has received 510(k)
clearance from the U. For more information on TriPath
Imaging please visit our web site at http://www. Copies
of filings made with the SEC are available through the SEC's electronic data
gathering analysis retrieval system (EDGAR) at http://www.

lum ungdom

Today's announcement continues the momentum at
Luminent to expand and improve our business model and results.

talvard endam

The reports that Luminent files with the
Securities and Exchange Commission contain a more complete description of
these and many other risks to which Luminent is subject.

talvard er

Luminent's
current principal activity is to invest in mortgage-backed securities and
loans, thereby providing capital to the single family residential housing
market.

TriPath Imaging Receives FDA 510(k) Clearance for HER-2/neu Application for Ventana Image Analysis System

Ventana develops, manufactures, and markets instrument/reagent systems
that automate slide preparation and staining in clinical histology and drug
discovery laboratories worldwide. Such forward-looking statements include, without limitation, those
related to the development of the interactive histology imaging system,
including expected additional 510(k) applications, and product development
efforts .

tar sk

Zyda, Senior Vice President and Chief Financial
Officer of Luminent, +1-415-486-2110, or ir@luminentcapital . "This expands our VIAS menu and, together with the previous
clearance for ER/PR, enables us to provide further value to pathologists.

ar talvard

Ventana's clinical systems are important
tools used in the diagnosis and treatment of cancer and infectious diseases. Past performance is
not indicative of future results.

ri singar

Contacts:
TriPath Imaging Ventana Medical Systems
Stephen P.

singar barna

About TriPath Imaging, Inc.tripathimaging.

barna hf

"We appointed a highly experienced mortgage finance professional as
President in March 2005." Luminent is organized and conducts its operations so as to qualify as
a real estate investment trust for federal income tax purposes.

, Chairman, President, and CEO of TriPath Imaging. These forward-looking statements
include , but are not limited to, statements regarding the marketing of
products and market acceptance of Ventana products. A full discussion of risks and uncertainties is
available in our most recent Annual Report filed with the Securities and
Exchange Commission (SEC) on Form 10-K and all subsequent SEC filings.

ungdom kfum

luminentcapital.
"FDA clearance for the analysis of HER2/neu clearly increases the utility
of VIAS as an aid to the clinical assessment of breast cancer," said Paul R. "We expect to
continue to further expand the application menu supported by VIAS with
additional 510(k) applications.

ir royskt

SAN FRANCISCO, Luminent Mortgage Capital
announced today that Gail P.

Ventana Safe Harbor Statement
This press release contains certain forward-looking statements within the
meaning of the Federal Securities laws.

umbo ar

Luminent faces many risks that could cause its actual
performance to differ materially from the results predicted by its
forward-looking statements, including, without limitation, the possibilities
that interest rates may change, that prepayment rates may change, that
mortgage-backed securities may not be available for purchase on favorable
terms, that borrowings to finance the purchase of assets may not be available
on favorable terms, that Luminent may not be able to maintain its
qualification as a REIT for federal tax purposes, that Luminent may experience
the risks associated with investing in real estate, including changes in
business conditions and the general economy, and that Luminent's hedging
strategies may not be effective.

royskt ar

"
"Luminent is evaluating expanding its mortgage platform beyond the agency
spread arbitrage sector of the mortgage -backed securities market," said Gail
Seneca. In
May 2005, the Companies announced 510(k) clearance for VIAS when used with the
Ventana Estrogen (ER) and Progesterone (PR) Receptor assays.

sk umbo

After a period of transition with the newly appointed Chief
Executive Officer at Seneca Capital Management , Gail's responsibility will be
solely to Luminent.S., headquartered in Burlington, North Carolina ,
develops, manufactures, markets and sells innovative solutions to improve the
clinical management of cancer, including detection, diagnosis, staging and
treatment.com.

About Ventana Medical Systems, Inc.

umbo um

Seneca announced her departure from
Seneca Capital Management by year end in order to work exclusively at
Luminent. The information set forth in
this news release represents management 's current expectations and intentions.D.

tar talvard

Luminent assumes no responsibility to issue updates to the forward-looking
matters discussed in this news release."
"We are pleased that TriPath Imaging has obtained this clearance," stated
Christopher Gleeson, President and Chief Executive Officer of Ventana Medical
Systems.